Novogen Ltd. through its subsidiary engages in the business of pharmaceutical drug development. The company's inaugural drug candidate CS-6 belongs to a new class of drug candidates known as Mitochondrial Electron Transfer Inhibitors that work by depriving the cancer cell of its main energy source. And technology breakthrough, CS-6 has had its electronic signature altered to substantially increase its ability to bind to its cancer cell target. CS-6 is being developed in the first instance for the treatment of temozolomide-resistant glioblastoma multiforme, the main form of primary brain cancer, and for late-stage chemo-refractory ovarian cancer. Novogen was founded by Graham Edmund Kelly in March 1994 and is headquartered in Hornsby, Australia.